ClinicalTrials.gg

Program

nivegacetor

A development code. Also written as “RO7269162” and “[ 14C]-labeled RO7269162”.

Its studies are mostly in Alzheimer Disease, led by Hoffmann-La Roche.

Furthest: phase 2, since May 3, 20242 company-led studies, 1 open or runningNext primary completion: Nov 19, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche21 open or runningphase 2since May 3, 2024May 3, 2024Nov 19, 2026phase 2 · NCT06402838
  • Named in Hoffmann-La Roche’s own pipeline as RG6289 nivegacetor, phase 2, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 3, 2024First study: phase 2 study in Alzheimer DiseaseFirst studyNCT06402838 · 256 enrolled · Chile, Denmark, France and more
  2. Dec 10, 2024Phase 1 study in Healthy VolunteersNCT06733298 · 8 enrolled · Netherlands

Ahead

  1. Nov 19, 2026Primary completion: phase 2 study in Alzheimer DiseaseNCT06402838

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06733298Healthy Volunteers · Netherlands1CompletedJan 29, 20258
NCT06402838Alzheimer Disease · Chile, Denmark, France and more2Active, not recruitingNov 19, 2026256

How it is read

Names in the registry

  • “RO7269162”, 1 entry
  • “[ 14C]-labeled RO7269162”, 1 entry

Codes read as this program: RO7269162.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.